Research & Development

Repertoire and Lilly join hands on autoimmune disease therapies

Repertoire Immune Medicines has collaborated with Eli Lilly and Company to develop tolerising therapies to treat several autoimmune diseases.

Sensorion announces $71.9m reserved offering to expand gene therapy pipeline

Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline.

Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies

Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center on drug development for cardiometabolic diseases.

Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline

Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver diseases.

Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis

Opna Bio has received the US Food and Drug Administration’s (FDA) orphan drug designation for OPN-2853 (zavabresib), a bromodomain and extra-terminal motif (BET) small molecule inhibitor, to treat myelofibrosis.

BMS and Microsoft partner for AI-based lung cancer detection

Bristol Myers Squibb (BMS) has entered an agreement with Microsoft to advance AI-driven early lung cancer detection.

Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies

Novo Nordisk and Aspect Biosystems have commenced a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes.

AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

AstraZeneca has agreed to purchase AbelZeta’s 50% stake in the China development and commercialisation rights for C-CAR031.

FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease

Novartis has announced that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to ianalumab, a treatment for Sjögren’s disease, the second most prevalent rheumatic autoimmune condition.